中國澱粉(03838.HK)設合營拓乳酸酯開發生產及銷售
中國澱粉(03838.HK)公布,於8月24日,公司間接全資附屬公司金遠東與合資夥伴就成立註冊資本為1億元人民幣(其中金遠東出資75%,合資夥伴出資餘下25%)之合資公司訂立合資協議。建議成立之合資公司主要從事乳酸酯及其他相關產品的研究、開發、生產及銷售。
合資公司計劃於壽光建造生產場地連同生產廠房及設施以作自用及經營。於本公告日期,合資公司或集團並無就或有關可能生產場地建造訂立具約束力之協議。倘可能生產場地建造得到落實,公司將遵守適用於或有關可能生產場地建造之上市規則之相關規定。
合資公司(公司佔75%股權)之財務業績將併入公司之業績。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.